ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1966

Transcriptome and Methylome Integrative Molecular Analysis Uncovers a New Systemic Autoimmune Disease Classification

Guillermo Barturen1, Sepideh Babaei2, Francesc Catala-Moll3, Zuzanna Makowska2, Antonio García-Gómez3, Anne Buttgereit4, Elena Carnero-Montoro1, Sikander Hayat4, Martin Kerick5, Thomas Charlon6, David C Gemperline7, Lucas Le Lann8, Rosa Quirantes-PIné9, Isabel Borrás-Linares10, Brian Muchmore1, Jorge Kageyama4, Javier Rodríguez-Ubreva3, Alvaro Fernández-Ochoa9, Pedro Carmona Sanz11, Christophe Jamin8, Ralf Lesche2, Robert J. Benschop7, Chris Chamberlain12, Ernst R. Dow7, Tania Gomes1, Maria Juárez13, Laurence Laigle14, Jacqueline Marovac12, Fiona MacDonald15, Jerome Wojcik6, Esteban Ballestar16, Lorenzo Beretta17, Maria Orietta Borghi18, Johan Frostegård19, Maria Luisa Garcia20, Javier Martín5, Jacques-Olivier Pers8, Yves Renadineau21, Antonio Segura Carretero9 and Marta Alarcón-Riquelme1,19, 1Medical Genomics, Center for Genomics and Oncological Research (GENYO), Granada, Spain, 2Pharmaceuticals Division, Bayer Pharma Aktiengesellschaft, Berlin, Germany, 3Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain, 4Bayer Pharma Aktiengesellschaft, Berlin, Germany, 5Institute of Parasitology and Biomedicine López Neyra, Spanish National Research Council, Granada, Spain, 6QuartzBIO, SA, Geneva, Switzerland, 7Eli Lilly and Company, Indianapolis, IN, 8U1227, Université de Brest, Inserm, Labex IGO, CHU de Brest, Brest, France, 9Department of Analytical Chemistry, University of Granada, Granada, Spain, 10Analytical Chemistry, University of Granada, Granada, Spain, 11Unit of Bioinformatics, Center for Genomics and Oncological Research (GENYO), Pfizer-University of Granada-Andalusian Regional Government, Health Sciences Technology Park, Granada, Spain, 12UCB Pharma, Slough, United Kingdom, 13UCB, Slough, United Kingdom, 14Institut de Recherches Internationales Servier, Suresnes, France, 15Bayer Pharma G, Berlin, Germany, 16Cancer Epigenetics and Biology Programme (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain, 17Scleroderma Unit, Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, 18University of Milan, IRCCS Istituto Auxologico Italiano, Milan, Italy, 19Unit for Chronic Inflammatory Diseases, Institute for Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, 20Nano-Imaging, BIONAND. Centro Andaluz de Nanotecnología y Biomedicina, Malaga, Spain, 21U1227, Université de Brest, inserm, Labex IGO, CHU de brest, Brest, France

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: genomics, methylation, Rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and systemic sclerosis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, October 23, 2018

Title: Genetics, Genomics and Proteomics Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic autoimmune diseases (SADs) are chronic inflammatory conditions with autoimmune aetiology and many common clinical features, difficulting diagnosis and adequate treatment decisions. Finding new treatments or applying the existing ones in a more effective way is especially hard in SADs due to the heterogeneity of molecular mechanisms within the same disease class. Based on this premise, the first step towards establishing a precision medicine strategy for SADs is to reclassify these conditions at the molecular level, which might result in a more homogenous stratification in terms of pathological molecular pathways. SADs have a multi-factorial predisposition, where the interplay between genetic, epigenetic and environmental conditions is essential in the pathogenesis of the diseases. Thus, in order to capture as many aspects as possible the molecular stratification is performed using multiple layers of information (e.g. genome, transcriptome, methylome or metabolome). Among all available molecular levels of information, the most informative in terms of functionality and dimensionality are transcriptome and methylome, reflecting different aspects of regulation and environmental influence, respectively, giving a wide view of the molecular background.

Methods: We performed an unsupervised integrative clustering analysis to classify SADs patients into subtypes based on genome-wide trancriptome and methylome profiling of ~800 cases distributed across 7 different clinical entities (rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, primary Sjögren ́s syndrome, primary antiphospholipid antibody syndrome, mixed connective tissue disease and undifferentiated connective tissue disease) and ~200 healthy individuals.

Results: Interestingly, patients with different diagnoses were grouped statistically into new groups in terms of molecular functions. These results were replicated in two independent subsets of patients. The new groups of patients are characterized by a major subdivision, where some clusters show an increased inflammatory response and neutrophil degranulation functions, while others are enriched in lymphocyte proliferation and differentiation signatures. This major signal is subdivided into more specific subgroups defined by functional signatures such as type I interferon signaling, complement activation or neural functionalities among others.

Conclusion: This is the first attempt of integrating and characterizing SADS patients based on molecular profiles. The results show that we are able to identify new groups of patients sharing molecular features that do not reflect the clinical diagnoses. This new molecular classification might suppose a first step through precision medicine in SADS.


Disclosure: G. Barturen, Sanofi, 2; S. Babaei, Bayer, 3; F. Catala-Moll, None; Z. Makowska, Bayer, 3; A. García-Gómez, None; A. Buttgereit, Bayer, 3; E. Carnero-Montoro, None; S. Hayat, Bayer, 3; M. Kerick, UCB, Inc., 2; T. Charlon, None; D. C. Gemperline, Eli Lilly and Co., 3; L. Le Lann, Servier, 2; R. Quirantes-PIné, EFPIA, 2; I. Borrás-Linares, EFPIA, 2; B. Muchmore, EFPIA, 2; J. Kageyama, Bayer, 3; J. Rodríguez-Ubreva, EFPIA, 2; A. Fernández-Ochoa, EFPIA, 2; P. Carmona Sanz, None; C. Jamin, Servier, 2; R. Lesche, Bayer, 3; R. J. Benschop, Eli Lilly and Company, 1, 3; C. Chamberlain, UCB, Inc., 3; E. R. Dow, Eli Lilly and Company, 1, 3; T. Gomes, EFPIA, 2; M. Juárez, UCB, Inc., 3; L. Laigle, Servier, 3; J. Marovac, UCB, Inc., 3; F. MacDonald, Bayer AG, 3; J. Wojcik, EFPIA, 2; E. Ballestar, None; L. Beretta, EFPIA, 2; M. O. Borghi, EFPIA, 2; J. Frostegård, EFPIA, 2; M. L. Garcia, EFPIA, 2; J. Martín, EFPIA, 2; J. O. Pers, None; Y. Renadineau, EFPIA, 2; A. Segura Carretero, EFPIA, 2; M. Alarcón-Riquelme, Sanofi, Bayer, UCB, Eli Lilly and Servier, 2.

To cite this abstract in AMA style:

Barturen G, Babaei S, Catala-Moll F, Makowska Z, García-Gómez A, Buttgereit A, Carnero-Montoro E, Hayat S, Kerick M, Charlon T, Gemperline DC, Le Lann L, Quirantes-PIné R, Borrás-Linares I, Muchmore B, Kageyama J, Rodríguez-Ubreva J, Fernández-Ochoa A, Carmona Sanz P, Jamin C, Lesche R, Benschop RJ, Chamberlain C, Dow ER, Gomes T, Juárez M, Laigle L, Marovac J, MacDonald F, Wojcik J, Ballestar E, Beretta L, Borghi MO, Frostegård J, Garcia ML, Martín J, Pers JO, Renadineau Y, Segura Carretero A, Alarcón-Riquelme M. Transcriptome and Methylome Integrative Molecular Analysis Uncovers a New Systemic Autoimmune Disease Classification [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/transcriptome-and-methylome-integrative-molecular-analysis-uncovers-a-new-systemic-autoimmune-disease-classification/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/transcriptome-and-methylome-integrative-molecular-analysis-uncovers-a-new-systemic-autoimmune-disease-classification/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology